Clinical Trials

The Translational Neuromuscular Disease Research Laboratory is actively involved in human clinical trials at all phases of therapeutic development. These studies are both initiated by Mayo Clinic investigators and arise out of collaborations with industry partners.

Dr. Staff's research team has led studies focused on mesenchymal stem cells (MSCs) in amyotrophic lateral sclerosis (ALS), having completed a Phase I first-in-human study and launched a Phase II study using these cells. Active clinical trials for the Translational Neuromuscular Disease Research Lab include:

• Intrathecal Autologous Adipose-Derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
• Safety and Efficacy of Repeated Administration of NurOwn in ALS Patients
• Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS